(Q44607327)

4 December 2017

title

A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events (English)

1 reference

4 December 2017

0 references

6

1 reference

4 December 2017

Andres M Kanner

1

1 reference

4 December 2017

Joanne Wuu

2

1 reference

4 December 2017

Edward Faught

3

1 reference

4 December 2017

William O Tatum

4

1 reference

4 December 2017

Aaron Fix

5

1 reference

4 December 2017

PADS Investigators

7

1 reference

4 December 2017

publication date

1 October 2003

1 reference

4 December 2017

1 reference

4 December 2017

volume

4

1 reference

4 December 2017

issue

5

1 reference

4 December 2017

page(s)

548-552

1 reference

Postmarketing experience with topiramate and cognition

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.07.007

A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.07.007

Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.07.007

Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.07.007

Acute psychotic symptoms induced by topiramate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.07.007

An audit of topiramate use in a general neurology clinic.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.07.007

Psychiatric comorbidity in chronic epilepsy: identification, consequences, and treatment of major depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.07.007

Depression in epilepsy: a common but often unrecognized comorbid malady

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.07.007

Topiramate monotherapy for partial onset seizures.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.07.007

Schizophrenia-like psychosis and epilepsy: the status of the association.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.07.007

Open-label adjunctive topiramate in the treatment of bipolar disorders.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.07.007

Use of topiramate, a new anti-epileptic as a mood stabilizer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.07.007

Prophylaxis of migraine, transformed migraine, and cluster headache with topiramate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.07.007

A systematic review of the safety profile of levetiracetam: a new antiepileptic drug.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.07.007

10.1016/J.YEBEH.2003.07.007

7 January 2021

Identifiers

DOI

1 reference

4 December 2017

1 reference